Connect with us

International

Hawkeye Systems Inc (OTCMKTS: HWKE) Breaking Out as Co Enters LOI to Acquire Blue Gold International Limited in Share Exchange Resulting in Reverse Takeover of Blue Gold

Hawkeye Systems Inc (OTCMKTS: HWKE) is making an explosive move up the charts after the Company announced it has entered into an LOI to acquire Blue Gold…

Published

on

Hawkeye Systems Inc (OTCMKTS: HWKE) is making an explosive move up the charts after the Company announced it has entered into an LOI to acquire Blue Gold International Limited an entity valued at US $250,000,000, in a share exchange that will result in a reverse takeover of Blue Gold by Hawkeye. The shareholders of Blue Gold International Limited will hold upward of 95% of Hawkeye post-acquisition. This is in effect a reverse merger with Blue Gold International being the surviving public Company. 

Reverse merger stocks can be more explosive than biotech’s when the incoming Company has real value but is undiscovered to investors and we have covered many on the website that have gone from pennies to dollars. In support of the transaction the Company appointed Christopher Mulgrew and James Kerby to the Board of Directors of Hawkeye. During the due diligence period, Hawkeye intends to complete a 1 for 10 reverse stock split and change the company name and ticker symbol. There will be a rebranding of the Company, finalization of the go-to-market plan, recruitment of a new management team, and further modification to the board of directors. Ghana is one of the leading producers of gold in Africa and the seventh leading Gold producer in the world. 

Subscribe To Our 100% Free Penny Stock Newsletter!

Hawkeye Systems Inc (OTCMKTS: HWKE) is a technology holding company which has focused on cutting edge technology, pandemic management products and services. The Company has made the decision in the current environment to become a diversified gold producer with the first asset being Blue Gold in Ghana. 

Microcapdialy has been covering HWKE for a while now reporting in February 2021: “HWKE has seen its stock price more than double on a day that the overall markets were deeply red. The stock jumped off its $0.35 base on a surge of volume and saw highs of $1.10 per share. The move on HWKE came after the Company LOI with Arizona Asian Pacific Trade and Consulting” 

HWKE is making an explosive move up the charts after the Company reported it signed an LOI to acquire Blue Gold International Limited an entity valued at US $250,000,000, in a share exchange that will result in a reverse takeover of Blue Gold by Hawkeye. The shareholders of Blue Gold International Limited will hold upward of 95% of Hawkeye post-acquisition. 

To Find out the inside Scoop on HWKE Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Blue Gold is the 90% owner and operator of the Bogoso Prestea goldmine in Ghana, which contains one of the most significant gold concessions in the world-famous Ashanti gold belt. As a diversified gold mining operator looking to acquire other prospective gold properties in Africa and elsewhere, Blue Gold will leverage its significant management expertise and an increasingly robust balance sheet. 

The transaction is subject to due diligence and definitive documentation and is expected, by all parties, to close by October 31, 2022. Hawkeye and Blue Gold intend to complete a $6 million funding arrangement prior to July 31, 2022 which will be invested into Blue Gold and serve as working capital during the due diligence period. Hawkeye has conjunctively terminated all other LOI’s and discussions with alternative opportunities it has been evaluating, as previously reported, as it believes Blue Gold represents the strongest potential upside for its shareholders. 

Hawkeye Chief Executive Officer Corby Marshall commented, “Following extensive analysis, we believe transitioning our strategy to become a diversified gold producer will enable the Company to capitalize on the inflationary and rising interest rate macroeconomic trends and provide the basis for a growing sustainable business. Given the project’s location in Ghana’s historically significant gold area, the Ashanti gold belt we are confident in our ability to build significant long-term shareholder value. The project has produced approximately 12 million ounces of gold since 1912.” 

Dan Owiredu, Chief Executive Officer of Blue Gold, stated, “We are pleased to be reentering the equity capital markets with a primary listing in the US through this transaction with Hawkeye. We actively seek to leverage the equity capital markets at a time of increasing interest in gold, a combination that we believe will also create a strong platform for us to fully develop the proven sulfide resource and the significant unexplored strike.” 

In support of the transaction the Company appointed Christopher Mulgrew and James Kerby to the Board of Directors of Hawkeye. During the due diligence period, Hawkeye intends to complete a 1 for 10 reverse stock split and change the company name and ticker symbol. There will be a rebranding of the Company, finalization of the go-to-market plan, recruitment of a new management team, and further modification to the board of directors. 

Blue International Holdings formed Blue Gold International in 2020 as a platform to acquire high quality long-term mining assets in sub Saharan Africa.  In October 2020 it acquired the gold producing Bogoso Prestea Gold Mine in the Ashanti gold belt in Ghana. Blue Gold owns 90% of the project, with the Government of Ghana holding the remaining 10% interest. Bogoso Prestea has the largest mining concessions (of any mineral) in Ghana, with an 82 kilometre gold strike within the Ashanti gold belt (one of the most prolific gold regions globally).  The Bogoso Prestea concession has 3.3m oz of proven gold reserves and production is expected to reach 70,000 oz in 2022.  Operational and financial performance has improved significantly under Blue Gold ownership. Blue Gold will be seeking to acquire and develop further gold producing assets over the coming years, with a view to a successful stock market listing. 

For More on HWKE Subscribe Right Now!

Currently trading at a market valuation of less than $1 million USD HWKE has 25,604,148 shares outstanding, 16,250,210 of which are restricted leaving 9,353,938 free trading shares. The Company is an SEC filer and fully reporting OTCQB with $1.6 million in liabilities on the books and the perfect reverse merger candidate. The stock is up big after the Company entered into an LOI to acquire Blue Gold International Limited an entity valued at US $250,000,000, in a share exchange that will result in a reverse takeover of Blue Gold by Hawkeye. The shareholders of Blue Gold International Limited will hold upward of 95% of Hawkeye post-acquisition. This is in effect a reverse merger with Blue Gold International being the surviving public Company. Ghana is one of the leading producers of gold in Africa and the seventh leading gold producer in the world.  We will be updating on HWKE when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HWKE.

WAIT! Do You Want Stocks That Could Go Up 348% In Days Delivered To Your Inbox For FREE?

Disclosure: we hold no position in HWKE either long or short and we have not been compensated for this article.

The post Hawkeye Systems Inc (OTCMKTS: HWKE) Breaking Out as Co Enters LOI to Acquire Blue Gold International Limited in Share Exchange Resulting in Reverse Takeover of Blue Gold first appeared on Micro Cap Daily.

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

International

Another country is getting ready to launch a visa for digital nomads

Early reports are saying Japan will soon have a digital nomad visa for high-earning foreigners.

Published

on

Over the last decade, the explosion of remote work that came as a result of improved technology and the pandemic has allowed an increasing number of people to become digital nomads. 

When looked at more broadly as anyone not required to come into a fixed office but instead moves between different locations such as the home and the coffee shop, the latest estimate shows that there were more than 35 million such workers in the world by the end of 2023 while over half of those come from the United States.

Related: There is a new list of cities that are best for digital nomads

While remote work has also allowed many to move to cheaper places and travel around the world while still bringing in income, working outside of one's home country requires either dual citizenship or work authorization — the global shift toward remote work has pushed many countries to launch specific digital nomad visas to boost their economies and bring in new residents.

Japan is a very popular destination for U.S. tourists. 

Shutterstock

This popular vacation destination will soon have a nomad visa

Spain, Portugal, Indonesia, Malaysia, Costa Rica, Brazil, Latvia and Malta are some of the countries currently offering specific visas for foreigners who want to live there while bringing in income from abroad.

More Travel:

With the exception of a few, Asian countries generally have stricter immigration laws and were much slower to launch these types of visas that some of the countries with weaker economies had as far back as 2015. As first reported by the Japan Times, the country's Immigration Services Agency ended up making the leap toward a visa for those who can earn more than ¥10 million ($68,300 USD) with income from another country.

The Japanese government has not yet worked out the specifics of how long the visa will be valid for or how much it will cost — public comment on the proposal is being accepted throughout next week. 

That said, early reports say the visa will be shorter than the typical digital nomad option that allows foreigners to live in a country for several years. The visa will reportedly be valid for six months or slightly longer but still no more than a year — along with the ability to work, this allows some to stay beyond the 90-day tourist period typically afforded to those from countries with visa-free agreements.

'Not be given a residence card of residence certificate'

While one will be able to reapply for the visa after the time runs out, this can only be done by exiting the country and being away for six months before coming back again — becoming a permanent resident on the pathway to citizenship is an entirely different process with much more strict requirements.

"Those living in Japan with the digital nomad visa will not be given a residence card or a residence certificate, which provide access to certain government benefits," reports the news outlet. "The visa cannot be renewed and must be reapplied for, with this only possible six months after leaving the countr

The visa will reportedly start in March and also allow holders to bring their spouses and families with them. To start using the visa, holders will also need to purchase private health insurance from their home country while taxes on any money one earns will also need to be paid through one's home country.

Read More

Continue Reading

Trending